Towards Healthcare
U.S. Oncology Drugs Market to Grow USD 246.85 Billion by 2034

U.S. Oncology Drugs Market Size & Future Scope 2025 - 2034 with Key Approvals

According to market projections, the U.S. oncology drugs sector is expected to grow from USD 95.69 billion in 2024 to USD 246.85 billion by 2034, reflecting a CAGR of 9.94%. The extensive research, scientific innovations, and the market penetration of several cancer-treating drugs drive the global expansion of the oncology field. The U.S. led the market owing to the aging population, advancements in targeted therapies, and drug innovations.

Content

  • Insight Code: 5985
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The U.S. oncology drugs market holds a valuation of USD 105.2 billion as of 2025, and will expand to USD 246.85 billion by 2034, achieving a CAGR of 9.94% between 2024 and 2034.

The U.S. oncology drugs market includes five segments such as drug class, therapy type, indication, dosage form, and distribution channel.

The key players in the U.S. oncology drugs market include GSK, Novartis, Johnson & Johnson, Pfizer, etc.

Key trends include newly approved diagnostics and therapeutics, such as several cancer-treating drugs that are approved by the U.S. FDA.

FDA, American Association for Cancer Research, NCI, etc.
Any Questions